Biota Pharmaceuticals Inc  

(Public, NASDAQ:BOTA)   Watch this stock  
Find more results for BOTA
+0.08 (3.43%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.32 - 2.41
52 week 2.10 - 5.82
Open 2.32
Vol / Avg. 0.00/71,438.00
Mkt cap 84.59M
P/E     -
Div/yield     -
EPS -0.21
Shares 35.10M
Beta 0.78
Inst. own 47%
May 4, 2015
Q3 2015 Biota Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 9, 2015
Biota Pharmaceuticals Inc at ROTH Conference
Feb 26, 2015
Biota Pharmaceuticals Inc to Acquire Anaconda Pharma Call
Feb 10, 2015
Biota Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
Feb 5, 2015
Q2 2015 Biota Pharmaceuticals Inc Earnings Release
Feb 5, 2015
Q2 2015 Biota Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 46.76% -16.01%
Operating margin 46.04% -16.74%
EBITD margin - -11.21%
Return on average assets 27.34% -11.01%
Return on average equity 32.53% -14.20%
Employees 66 -
CDP Score - -


2500 Northwinds Pkwy Ste 100
ALPHARETTA, GA 30009-2248
United States - Map
+1-678-2213343 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Biota Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing oral, small molecule compounds to treat respiratory-related viral infections. The Company�s clinical-stage program is laninamivir octanoate, a long-acting neuraminidase inhibitor (NI). It is also engaged in developing BTA-798, also known as vapendavir, which is in Phase 2 for the treatment of human rhinovirus (HRV) infections in patients with moderate to severe asthma. The Company�s Zanamivir is marketed around the world by GlaxoSmithKline plc as Relenza for the prevention and treatment of Influenza A and B. Its Laninamivir Octanoate is marketed by Daiichi Sankyo as Inavir across Japan for the treatment of influenza A and B in adults and children. The lead product from the Company�s collaboration with Daiichi Sankyo for a new class of inhaled long acting NI�s is LANI, also known as CS-8958, which is marketed in Japan as Inavir for the treatment of influenza A and B infections.

Officers and directors

Peter J. Azzarello CPA Chief Accounting Officer, Vice President - Finance
Age: 43
Bio & Compensation  - Reuters
Russell H. Plumb Executive Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Joseph M. Patti Ph.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
James Charles Fox Ph.D. Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Geoffrey F. Cox Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Michael R. Dougherty Independent Director
Age: 57
Bio & Compensation  - Reuters
John P. Richard Independent Director
Age: 57
Bio & Compensation  - Reuters
Anne M. VanLent Independent Director
Age: 66
Bio & Compensation  - Reuters